Sana Biotechnology (NASDAQ:SANA) Hits New 12-Month Low - What's Next?

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as $2.82 and last traded at $2.84, with a volume of 341149 shares trading hands. The stock had previously closed at $3.01.

Analyst Ratings Changes

A number of analysts have commented on SANA shares. HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Sana Biotechnology in a research note on Monday. JMP Securities lowered shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th. Finally, Citigroup increased their price objective on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a "buy" rating in a research report on Friday, August 9th.

Sana Biotechnology Price Performance

The company has a market capitalization of $642.93 million, a P/E ratio of -2.06 and a beta of 1.44. The company's 50-day moving average price is $4.14 and its two-hundred day moving average price is $5.73.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. On average, analysts anticipate that Sana Biotechnology, Inc. will post -1.13 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Richard Mulligan sold 150,000 shares of the firm's stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the transaction, the director now directly owns 2,848,121 shares of the company's stock, valued at approximately $11,620,333.68. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 31.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds have recently bought and sold shares of the company. ProShare Advisors LLC increased its holdings in Sana Biotechnology by 14.8% in the 1st quarter. ProShare Advisors LLC now owns 32,690 shares of the company's stock valued at $327,000 after buying an additional 4,210 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Sana Biotechnology by 20.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company's stock valued at $163,000 after buying an additional 5,090 shares during the period. Arizona State Retirement System increased its holdings in Sana Biotechnology by 36.7% in the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company's stock valued at $202,000 after buying an additional 9,940 shares during the period. Blue Trust Inc. increased its holdings in Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock valued at $55,000 after buying an additional 12,154 shares during the period. Finally, Algert Global LLC bought a new position in Sana Biotechnology in the 2nd quarter valued at about $73,000. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.